More Stories

Informist, Thursday, Aug. 13, 2026

 

Please click here to read all liners published on this story

--Ipca Lab Apr-Jun consol net profit INR 4.02 bln
--Analysts saw Ipca Lab Apr-Jun consol net profit at INR 3.10 bln
--Ipca Lab Apr-Jun consol revenue INR 27.88 bln
--Analysts saw Ipca Lab Apr-Jun consol revenue at INR 25.61 bln
--Ipca Lab Apr-Jun consol net profit INR 4.02 bln vs INR 2.33 bln year ago
--Ipca Lab Apr-Jun consol revenue INR 27.88 bln vs INR 23.09 bln year ago
--Ipca Lab Apr-Jun consol India sales INR 12.29 bln vs INR 10.83 bln yr ago
--Ipca Lab Q1 consol outside India sales INR 15.6 bln vs INR 12.3 bln yr ago
--Ipca Lab Q1 consol EBITDA INR 6.38 bln vs INR 4.25 bln year ago
--Ipca Lab Q1 formulation sales INR 16.85 bln vs INR 14.11 bln year ago
--Ipca Lab Apr-Jun API sales INR 4.24 bln vs INR 3.26 bln year ago
--Ipca Lab Apr-Jun consol EBITDA margin 22.88% vs 18.39% year ago
 

 

By Ayush Jaiswal

 

MUMBAI – IPCA Laboratories Ltd. Thursday reported a significant jump in its net profit for the June quarter on the back of strong revenue growth and robust expansion in margins. The company's net profit beat analysts' expectations by 30%. The growth in revenue from operations was the fastest in the last eight quarters. 

 

IPCA Lab's consolidated net profit rose 72% to INR 4.02 billion from INR 2.33 billion in the year-ago quarter. Analysts had estimated the company's net profit at INR 3.10 billion. The company's consolidated revenue from operations was INR 27.88 billion, up 21% on year from INR 23.09 billion. Analysts had estimated the company's revenue from operations at INR 25.61 billion. The revenue growth was driven by broad-based growth across all segments.

 

The company's total expenses rose 11% on year to INR 22.41 billion. Slower growth in expenses compared to revenue also resulted in a significant jump in the company's net profit. Its other expenses rose 9% on year to INR 7.20 billion. Cost of material consumed was 6.38 billion, up 3% on year, and employee benefit expense rose 11% to INR 6.02 billion. 

 

IPCA Lab's sales from India rose over 13% on year to INR 12.29 billion, while its revenue from outside India rose 27% on year to INR 15.59 billion. The company's sales from its formulation business were at INR 16.85 billion, up 19% on year. Its sales from the active pharmaceutical ingredients business rose 30% on year to INR 4.24 billion.

 

The company's earnings before interest, tax, depreciation, and amortisation were INR 6.38 billion, up 50% on year. The EBITDA margin increased to 22.88% from 18.39% in the year-ago quarter.

 

The company detailed its June quarter earnings during market hours. Shares of the company were up over 5% at INR 1,864.6 apiece on the National Stock Exchange at 1333 IST, before the company announced its results. The shares hit a high of INR 1,905 after the results were announced. At 1415 IST, shares of the company were at INR 1,812.90 apiece on the NSE, up 2.6%.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.